ANK3 ankyrin 3
ENSG00000151150 · protein coding · Open Targets profile
Required for the organization of specialized membrane domains by linking the membrane to the cytoskeleton (PubMed:7836469). In neurons, participates in the maintenance/targeting of ion channels and cell adhesion molecules at the nodes of Ranvier and axonal initial segments (PubMed:7836469). In skeletal muscle, required for the localization of dystrophin (DMD) and beta-dystroglycan (betaDAG1) to costameres (By similarity). In rod photoreceptors, required for the transport of cyclic nucleotide-gated (CNG) channel subunits from the inner segment to the sensory cilium outer segment, which is critical for phototransduction and outer segment morphogenesis (PubMed:19299621). Regulates the activity of the potassium channel KCNA1 in response to dietary Mg(2+) levels, contributing to renal Mg(2+) reabsorption (PubMed:23903368). Promotes intracellular adhesion and junctional conductance in myocytes by stabilizing GJA1/CX43 protein abundance and facilitating the localization of PKP2, GJA1/CX43, and SCN5A/Nav1.5 to cell-cell junctions (By similarity). {ECO:0000250|UniProtKB:G5E8K5, ECO:0000250|UniProtKB:O70511, ECO:0000269|PubMed:19299621, ECO:0000269|PubMed:23903368, ECO:0000269|PubMed:7836469}.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Antibody
- UniProt loc high conf, GO CC high conf, UniProt loc med conf, Human Protein Atlas loc
- PROTAC
- Database Ubiquitination, Half-life Data
gnomAD loss of function constraint: o/e 0.15365999937057495 (upper bound 0.19158999621868134). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
No named investigators on registry trials of ANK3's approved or late-stage drugs in the last three years.
No terminated, withdrawn or suspended trials of ANK3's drugs are registered
All 0 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.
| Drug | Type | Highest stage | Indications | Source records |
|---|---|---|---|---|
| No drugs or clinical candidates recorded. | ||||